Drug class linked to worse outcomes after transplant

Drug class linked to worse outcomes after transplant
Kidney transplant patients who receive mammalian target of rapamycin inhibitors after transplant have a greater probability of death or transplant failure than patients receiving calcineurin inhibitors, according to a study published online Oct. 1 in the American Journal of Transplantation.

(HealthDay)—Kidney transplant patients who receive mammalian target of rapamycin (mTOR) inhibitors after transplant have a greater probability of death or transplant failure than patients receiving calcineurin inhibitors, according to a study published online Oct. 1 in the American Journal of Transplantation.

Tamara Isakova, M.D., from the University of Miami, and colleagues compared clinical outcomes in 139,370 in the United States receiving mTOR inhibitors or (3,237 receiving mTOR inhibitors; 125,623 receiving calcineurin inhibitors; and 10,510 receiving both).

The researchers found that, in the two years after transplant, patients taking mTOR inhibitors alone had a higher risk of allograft failure and death than patients taking calcineurin inhibitors alone (hazard ratio [HR], 3.67 after discharge and 1.40 by year two). Between two and eight years later, patients taking mTOR inhibitors alone had a higher risk of death (HR, 1.25) and a higher risk of the composite of allograft failure or death (HR, 1.17) than patients taking calcineurin inhibitors alone. The risk was intermediate for patients taking both classes of drugs.

"Compared with calcineurin inhibitor-based regimens, use of an mTOR inhibitor-based regimen for primary immunosuppression in was associated with inferior recipient survival," Isakova and colleagues conclude.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Time to stop giving toxic drugs to kidney transplant patients?

date Sep 22, 2011

Patients who receive kidney transplants must take lifelong medications that, while preventing organ rejection, can also compromise other aspects of health. Immunosuppresive drugs called calcineurin inhibitors protect transplanted ...

Immunosuppressant switch cuts skin cancer post-transplant

date Jul 26, 2012

(HealthDay) -- In kidney-transplant patients with at least one cutaneous squamous-cell carcinoma, switching immunosuppressants (from calcineurin inhibitors to sirolimus) is associated with increased skin cancer-free ...

Recommended for you

New software helps improve surgical safety

date Apr 13, 2015

Because the spine is made up of repeating elements that look alike, surgeons can mistakenly operate on the wrong vertebra. To avoid this, Johns Hopkins researchers have developed a software program that works ...

Can facial plastic surgery make you more likeable?

date Apr 09, 2015

Facial plastic surgery may do more than make you look youthful. It could change—for the better—how people perceive you. The first study of its kind to examine perception after plastic surgery finds that ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.